Brummer Multi Strategy AB Invests $1.94 Million in Abivax SA Sponsored ADR $ABVX

Brummer Multi Strategy AB purchased a new position in Abivax SA Sponsored ADR (NASDAQ:ABVX) during the fourth quarter, HoldingsChannel reports. The firm purchased 14,375 shares of the company’s stock, valued at approximately $1,939,000. Abivax accounts for about 11.7% of Brummer Multi Strategy AB’s investment portfolio, making the stock its 4th largest position.

A number of other hedge funds have also recently made changes to their positions in ABVX. UBS Group AG grew its holdings in Abivax by 2,561.0% during the 3rd quarter. UBS Group AG now owns 4,461,262 shares of the company’s stock worth $378,761,000 after acquiring an additional 4,293,606 shares in the last quarter. Darwin Global Management Ltd. bought a new position in Abivax during the 3rd quarter worth about $263,698,000. Paradigm Biocapital Advisors LP bought a new position in Abivax during the 3rd quarter worth about $132,800,000. TCG Crossover Management LLC grew its holdings in Abivax by 17.4% during the 3rd quarter. TCG Crossover Management LLC now owns 7,111,596 shares of the company’s stock worth $603,774,000 after acquiring an additional 1,055,000 shares in the last quarter. Finally, Vestal Point Capital LP bought a new position in Abivax during the 3rd quarter worth about $84,900,000. 47.91% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on ABVX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Abivax in a report on Monday, April 20th. Barclays increased their target price on shares of Abivax from $142.00 to $148.00 and gave the stock an “overweight” rating in a report on Tuesday, March 24th. Wall Street Zen cut shares of Abivax from a “hold” rating to a “sell” rating in a report on Sunday, April 26th. Oddo Bhf restated an “outperform” rating on shares of Abivax in a report on Thursday, April 9th. Finally, Jefferies Financial Group started coverage on shares of Abivax in a report on Monday, March 16th. They issued a “buy” rating and a $160.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $137.15.

Abivax Price Performance

ABVX stock opened at $122.74 on Monday. The firm has a 50 day moving average of $116.69 and a 200 day moving average of $117.23. The stock has a market capitalization of $9.73 billion, a PE ratio of -22.86 and a beta of 0.84. Abivax SA Sponsored ADR has a 52 week low of $5.59 and a 52 week high of $148.83.

Abivax (NASDAQ:ABVX) last released its earnings results on Saturday, February 14th. The company reported ($1.20) EPS for the quarter. The company had revenue of $0.52 million for the quarter. On average, equities research analysts expect that Abivax SA Sponsored ADR will post -3.84 earnings per share for the current year.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.